Evidence map›Paper›PMID 39866929›Full record

ArticleEJHaem2025

Increased serum B-cell maturation antigen levels evaluated with an Elecsys-based serum B-cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma.

Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Foteini Theodorakakou, Maria Roussou, Maria Gavriatopoulou, Meletios A Dimopoulos and 1 more

Abstract read
In one paragraph

Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Evangelos TerposDepartment of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID https://orcid.org/0000-0001-5133-1422
Ioannis Ntanasis-StathopoulosDepartment of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID https://orcid.org/0000-0002-6328-9783
Panagiotis MalandrakisDepartment of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID https://orcid.org/0000-0002-4673-171X
Despina FotiouDepartment of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID https://orcid.org/0000-0002-0618-8900
Magdalini MigkouDepartment of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID https://orcid.org/0000-0003-0131-2447
Evangelos Eleutherakis-PapaiakovouDepartment of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID https://orcid.org/0000-0003-3407-5994
Foteini TheodorakakouDepartment of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID https://orcid.org/0000-0001-6926-0351
Maria RoussouDepartment of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Athens Greece.
Maria GavriatopoulouDepartment of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID https://orcid.org/0000-0002-6244-1229
Meletios A DimopoulosDepartment of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID https://orcid.org/0000-0001-8990-3254
Efstathios KastritisDepartment of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Athens Greece.ORCID https://orcid.org/0000-0001-8191-5832

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSerum B-cell maturation antigen (sBCMA) levels have emerged as a potential biomarker for disease monitoring in multiple myeloma (MM) with prognostic value.

methodsHerein, we evaluated the sBCMA levels in 166 patients with newly diagnosed MM with an Elecsys-based sBCMA assay.

resultsIncreased sBCMA levels at diagnosis were correlated with inferior survival outcomes in terms of both progression-free and overall survival. In a subset of patients with available samples at the time of disease progression, there was a trend for decreasing sBCMA values.

conclusionSequential evaluation of sBCMA in prospective studies will determine the value of incorporating sBCMA measurement in clinical practice.

Indexed as

B‐cell maturation antigenBCMAmultiple myelomaoverall survivalprognosisprogression‐free survival

Identifiers

PMID39866929
PMCPMC11756978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.